Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

The year 2021 is marked by several articles aimed at better risk stratification of osteoporosis to define the groups of patients at very high risk of fractures or at imminent risk of fractures. This stratification determines who should benefit from a first line bone anabolic treatment. A review of the current state of osteoporosis was therefore essential; it shows that Switzerland is lagging. In terms of prevention of bone fragility, dairy products are probably a leading strategy, especially in the elderly. The practical management of denosumab discontinuation is finally better understood. Finally, with the arrival of a new treatment, Burosumab, we are experiencing a therapeutic revolution for rare hypophosphatemic diseases.


Elena Gonzalez Rodriguez, Anne-Cécile Debrach-Schneider, Olivier Lamy. Osteoporosis]. Revue medicale suisse. 2022 Jan 19;18(764-5):56-58

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 35048581

View Full Text